PEAK1 Acts as a Molecular Switch to Regulate Context-Dependent TGFβ Responses in Breast Cancer
(A) PEAK1 mRNA fold change was analyzed from several previous reports of patient data in relation to characteristics that correlate with poor patient prognosis–i.e., metastatic lesions, disease relapse, advanced N stage, high grade, HER2 positive status, and stromal-derived poor prognostic (SDPP) status. (B) IHC from the Human Cancer Atlas of four different patients–two with elevated PEAK1 levels and two with low PEAK1 levels–for SNAI1, FN1, OCLN and ESR1 expression. (C) Western blot analysis on lysates from MCF10A, MCF10AT1K, MCF10CA1h, and MCF10CA1a cells for PEAK1 and E-cadherin expression. (D) Single cell migration assay on 3μg/mL of Fibronectin (F), Collagen (C), or Laminin (L) of CA1h and CA1a cells (velocity is plotted on the left axis and displacement is plotted on the right). (E) MCF10A, CA1h, MDA-MB-231, and MCF7 cells were plated on plastic and treated for 72 hours with TGFβ. RNA was collected and qPCR for E-cadherin (top) and PEAK1 (bottom) expression was performed. ** or *** indicate p-values < 0.01 or 0.001, respectively.